Objectives: The management of recurrent NSCLC in the setting of prior radiation therapy is challenging. Proton radiotherapy (PRT) is ideally suited to minimize toxicity to previously irradiated organs. We report the safety/feasibility of PRT for NSCLC reirradiation in a prospective multiinstitutional study.
Introduction
NSCLC recurrence in the thorax poses significant treatment challenges. Although patients initially presenting with locally advanced NSCLC treated with concurrent chemoradiation most often fail by distant metastasis (DM), there is a 25% risk of isolated locoregional failure. 1 Giving radiotherapy (RT) at recurrence is challenging, as it is estimated that 76% of patients with lung cancer benefit from receiving RT at initial presentation. 2 When tumors recur in prior radiation fields and without evidence of distant metastatic disease, consideration could be given to a potentially curative option.
Generally, chemotherapy has shown low response rates, 3, 4 prompting a search for alternative methods to achieve durable locoregional response, such as surgery or reirradiation. The risks of thoracic surgery after prior definitive radiation therapy are often prohibitive. 5 Likewise, radiation oncologists are often hesitant to reirradiate because of concern for excess toxicities to the heart, lungs, spinal cord, and esophagus when attempting to achieve a curative dose. 6 Proton RT (PRT) is ideally suited to the challenge of reirradiation. Its characteristic Bragg Peak allows for rapid falloff of irradiation dose at the distal edge of the target, sparing normal tissues that have already received high doses from prior radiation. 7 Multiple studies have examined reirradiation in NSCLC, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] including recent retrospective studies exploring proton reirradiation. [20] [21] [22] These studies have been limited by factors such as small patient numbers, the retrospective nature of the analyses, and heterogeneity in treatment techniques and patient populations.
Herein, we report the multi-institutional, prospective results of PRT for NSCLC reirradiation across three institutions. We report the clinical outcomes of the largest patient cohort to date receiving PRT for locally recurrent NSCLC, and we detail novel dosimetric parameters and their correlation with toxicity for proton reirradiation. We aimed to define predictors of toxicity and outcomes and to provide preliminary guidance on patient selection for this treatment approach.
Materials and Methods

Patient Inclusion
This study was performed in accordance with the institutional review board at the University of Pennsylvania. Our center launched a prospective trial of PRT for the reirradiation of recurrent malignancies stratified by disease site (head and neck, thorax, abdomen and pelvis, and extremity). This study was opened at the Northwestern Medicine Chicago Proton Center in Warrenville, Illinois, and the ProCure Proton Therapy Center in Oklahoma City, Oklahoma. The trial is registered on ClinicalTrials.gov as NCT01126476. The patients who received PRT for recurrent NSCLC in the thoracic cohort of the larger trial from October 2010 through December 2015 were included in this analysis.
All patients in this study were adults, age 18 years or older, who completed an initial course of RT for NSCLC at least 3 months prior, either at a study institution or at an outside facility. Patients were required to have an Eastern Cooperative Group performance status of 2 or lower and a life expectancy of at least 3 months. Patients were stratified as either low volume (ratio of clinical target volume to internal target volume [CTV/ITV ratio] <250 cm 3 ) or high volume (CTV/ITV ratio !250 cm 3 ). Primary end points included feasibility and acute toxicity, and secondary end points included late complications, local control, overall and disease-specific survival, and comparison of dose-volume histograms (DVH) of the PRT plan and the backup photon plan generated for clinical purposes.
Definition of Target Volume and OAR
The ITV was defined as the volume of recurrent gross tumor or tumor bed plus a margin for microscopic disease according to the clinical judgment of the treating radiation oncologist after accounting for motion on the basis of a four-dimensional computed tomography (CT) scan. All patients underwent positron emission tomography/CT at the time of simulation; all fludeoxyglucose F 18-avid activity identified by visualization was included in the gross tumor volume. A planning target volume (PTV) was defined to account for patient positioning and uncertainties regarding beam delivery (0.5-1 cm) per International Commission on Radiation Units and Measurements reports 62 and 78. Organs-at-risk (OAR) were defined for all patients, including the central airway region, which was defined as a volume 2 cm in all directions around the proximal bronchial tree.
Treatment Planning
Double-scatter or pencil beam scanning proton plans were generated by using the Eclipse Treatment Planning System, version 10.0.28 (proton convolution superposition models) (Varian Medical Systems, Palo Alto, CA); uniform scanning plans were generated using the Xio Treatment Planning System, version 5.0 (pencil beam algorithm 23 ) (Impac Medical Systems, Maryland Heights, MO). For proton beam planning, in addition to the lateral margins included in the PTV, proximal and distal margins were added to account for range uncertainties along the beam direction. The axial margins were calculated as 3.5% of the distal and proximal water-equivalent path length relative to the ITV to account for uncertainty associated with CT calibration plus an additional 3 mm to account for range uncertainty from beam delivery. Single-field optimization was used for proton planning, and each proton field was designed to uniformly cover the target. All proton plans were designed by using a limited number of predominantly posterior and posterior oblique fields (most often two or three). All dose calculations were performed by using a 2.5 Â 2.5 Â 1.5-mm 3 grid, where 1.5 mm was the slice thickness of CT scans. All PRT plans were physician reviewed and approved for patient treatment. All proton doses included a generic mean relative biological effectiveness (RBE) of 1.1, as is standard per the International Commission on Radiation Units and Measurements report 78, and were reported in Gy (mean RBE). 24, 25 For quality assurance, daily image guidance with kilovoltagekilovoltage imaging was performed along with weekly offline CT verification.
DVH Analysis
Composite treatment plans were generated from the initial treatment course and the prospective proton reirradiation course. DVHs were analyzed and reirradiation planning was deemed feasible on the basis of the following protocol guidelines: 99% of the CTV covered by 98% of the prescription dose, 98% of the PTV covered by 95% of the prescription dose (within 5%), and a maximum cumulative point dose to the spinal cord of 75 Gy (RBE). Dosimetric data from three patients were unavailable on account of corrupted treatment planning files caused by software upgrades.
Follow-up
Subjects were evaluated 1 month after completion of PRT and then every 3 to 6 months with chest CT and/or positron emission tomography/CT scans. Acute toxicity was defined as any adverse event observed within 90 days from the initiation of RT that could be directly related to PRT. Toxicities were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Toxicities were designated by the study's principal investigator as definitely, probably, possibly, unlikely, or not related to proton reirradiation. Adverse events unrelated or unlikely to be related were not reported. The study's principal investigator was not the treating physician for any patients in this analysis. Toxicity attributions were also separately reviewed by the medical monitor and the data safety 26 The most recent follow-up clinic date or date of death was used to measure overall survival, and the last clinic date was used to calculate disease progression.
Statistical Analysis
The feasibility end point was defined such that a patient cohort was considered infeasible for continued treatment if more than 10% of patients were unable to have a dosimetrically satisfactory treatment plan described earlier, tolerate 85% of treatments using PRT, complete all treatments within 10 days of the estimated date of treatment completion, or required a treatment break longer than 5 days. Fisher's exact test was used for analysis of associations between categorical variables. Survival outcomes were estimated by Kaplan-Meier analysis. For all statistical comparisons, p values less than 0.05 were considered significant. All statistical analyses were performed by using R, version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria). 27 
Results
Patient Characteristics
Characteristics of the 57 patients in the study are provided in Table 1 . The median time between the original and reirradiation course was 19 months (range 3.5-151). Patients completed the prior course of radiation therapy from March 2001 to March 2015. Composite plan sums were generated for 39 patients; 18 patients did not have prior treatment course data available at the time of this analysis. For the readers' reference, a representative treatment plan is included to illustrate information regarding beam angles and dose distribution (Fig. 1) . The median prescription dose in the reirradiation setting was 66.6 Gy (range 30-74 Gy). More than two-thirds of patients (68%) received concurrent chemotherapy. The median CTV was 107.9 cm 
Feasibility
At the initiation of the study, patients were stratified as either low volume (CTV <250 cm 3 ) or high volume (CTV !250 cm 3 ). The high-volume patients in the full thoracic cohort of the proton reirradiation protocol were subsequently deemed infeasible because of inability to complete the prescribed treatment course owing to toxicity. Per early stopping rules, this cohort was suspended to further enrollment in August 2012. Fifty-two of the patients in this series (91%) were able to complete the prescribed course. Of the five patients with early discontinuation of treatment, one had progressive disease and the remaining four stopped early on account of treatment toxicity. This includes one patient with a high-tumor volume who experienced grade 5 bronchopulmonary hemorrhage after presenting with hemoptysis before starting PRT and a T4 endobronchial invasive tumor and likely bronchovascular fistula.
Predictors of Toxicity
Grade 3 or higher toxicity (acute or late) developed in 24 patients (42%). Of these, 22 (39%) presented with acute toxicity and seven (12%) presented with late toxicity. Four cases of grade 4 toxicity were observed (three neutropenia and one pericardial effusion) and six grade 5 toxicity events were observed (Tables 2 and 3 ). The 1-year actuarial rate of any grade 3 or higher toxicity was 55% and the median time to development of grade 3 or higher toxicity was not reached (Fig. 2) .
Proximity to central airway structures was associated with higher toxicity rates. When the central region was defined as the proximal bronchial tree plus 2 cm, we identified the volume of overlap of the reirradiation treatment volume with this region. The median amount of central region overlap seen in this series was 41 Table 2 ).
We analyzed the impact of increased composite dose to the critical normal structures of the esophagus and the heart. This was assessed by comparing the patients who had a mean esophagus dose above the mean of all esophageal mean doses (1245 cGy) seen in the patients on this study with available dosimetric data with the patients having a mean esophageal dose below the cohort mean. Acute grade 3 or higher toxicity developed in 14 of 22 patients with a high mean esophageal dose (64%) compared with in seven of 32 patients with a low esophageal mean dose (22%) (p ¼ 0.003). A similar analysis examining the composite mean heart dose was performed. Toxicity developed in 12 of 20 patients (60%) with a mean heart dose above the cohort mean (394 cGy) compared with in nine of 34 patients (26%) with a low mean heart dose (p ¼ 0.02) (see Table 2 ).
Patients receiving concurrent chemotherapy exhibited significantly higher rates of grade 3 or higher acute toxicity. Toxicity developed in 20 of 38 patients (53%) receiving concurrent chemotherapy compared with in three of 19 patients (16%) not receiving concurrent chemotherapy (p ¼ 0.003) (see Table 2 ).
Disease-Specific Outcomes and Survival
By the date of last follow-up, 24 patients (42%) had died, with a median follow-up time of 7.8 months (range 1-40 months) among all patients and 9.8 (range 1-40 months) among living patients (n ¼ 33). Eighteen (32%) patients were alive without evidence of locoregional recurrence (LR) or DM. Fourteen patients (25%) had evidence of LR, and DM developed in six (11%) after reirradiation ( Table 4) .
The 1-and 2-year rates of overall survival and progression-free survival were 59% and 43% and 58% 
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Grade ≥3 Toxicity Probability Figure 2 . Actuarial time to grade 3 or higher toxicity. Time to and rate of development of any grade 3 or higher toxicity event for all patients in study cohort. and 38%, respectively ( Fig. 3A and B) . Median overall survival was 14.9 months. We observed no significant increase in overall survival at 1 year with decreased volume of central region overlap (63% versus 55%, p ¼ 0.3) (Fig. 3C ). There was also no significant change in 1-year overall survival with patients who received concurrent chemotherapy (66% versus 43%, p ¼ 0.3) (Fig. 3D ). There was no difference in 1-year overall survival seen when patients in the low-mean heart dose group were compared with those in the high-mean heart dose group (59% versus 57%, p ¼ 0.8) (Fig. 3E ). However, patients with a low mean esophageal dose did exhibit significantly better 1-year overall survival compared with patients with a high mean esophageal dose (74% versus 38%, p ¼ 0.007) (Fig. 3F ).
Discussion
We have reported the results of our multiinstitutional, prospective experience with definitive intent reirradiation for recurrent NSCLC using PRT, which is the largest such study published to date. The subject of reirradiation for recurrent NSCLC has been explored in several contexts, and a comprehensive review of the existing literature has also been published recently. 28 Although there are many prior studies that have explored the role of thoracic reirradiation (Table 5) , 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 21, 22, [29] [30] [31] many of those initial studies were focused on the palliative aspects of NSCLC retreatment. 8, 9 In the context of reirradiation with definitive intent, some centers have favored using stereotactic body radiation therapy (SBRT) for NSCLC reirradiation. Hypofractionated retreatment regimens were first introduced by Kramer et al. 10 Others followed, utilizing SBRT as a means to limit dose to normal tissue while delivering radiation doses consistent with curative intent. 6, 12, 14, 16, 32 PRT has emerged as a potentially efficacious lung retreatment modality, given its known advantages in limiting integral dose and sparing normal tissue. 33 In recent years, two studies published by investigators at the MD Anderson Cancer Center 21, 22 have examined the outcomes in patient series using PRT, suggesting that these regimens are tolerable and safe but remain associated with significant toxicities and suboptimal local control rates and overall survival. This study adds an additional perspective to this challenging problem.
In concordance with prior similar series, 21, 22 we find that reirradiation can feasibly be delivered to completion, with more than 90% of patients completing the prescribed regimen. Jeremic et al. 11 provided a review of chest reirradiation of locally recurrent NSCLC. They showed a range of median survival time from 3 to 14 months, with 1-and 2-year survival rates ranging from 13% to 59% and 6% to 21%, respectively. In our study, the median survival was 15 months and the 1-and 2-year overall survival rates were 59% and 43%, respectively. We found that although reirradiation can be reliably completed, there is ample room for improvements in survival.
The rates of severe treatment-related toxicities were noteworthy, with grade 3 or higher toxicity developing in 39% of patients, resulting in six toxicity-related deaths (see Table 3 ). Our rates of toxicity were comparable to those in similar series. 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 21, 22, [29] [30] [31] It should be noted, however, that many of the patients in those prior studies were treated with palliative intent to lower overall doses. Thus, the use of modern, conformal techniques may allow for dose escalation and improved chance of prolonged locoregional control and survival without increased toxicity.
With regard to clinical and dosimetric factors affecting toxicity and survival outcomes, we posited that as in the initial SBRT studies by Timmerman et al., 34 tumor location and proximity to critical central airway structures may be predictive of toxicity. In our series, we observed at least two instances of grade 5 toxicities (bronchopulmonary hemorrhage and tracheoesophageal fistula) that were likely influenced by the degree of overlap with the central airway. We found that location is indeed important, as we observed significantly increased rates of grade 3 or higher toxicities with higher central region overlap (see Table 2 ). A small series of patients treated with PRT previously showed a trend toward increased toxicity for centrally located tumors, 22 a finding also described in a separate series using SBRT. 19 The series from MD Anderson Cancer Center using PRT or intensity-modulated radiation therapy for reirradiation also compared central and peripheral tumors. 21 This analysis did not specifically report on rates of toxicity; as in our study, however, there was no significant association between location and survival (hazard ratio ¼ 1.44, 95% confidence interval: 0.79-2.63, p ¼ 0.233).
One means of continued dosimetric improvement is through the increased use of intensity-modulated proton therapy (IMPT) techniques. The proton reirradiation plans used in this study were largely double-scatter plans (n ¼34 [59.6%]) or uniform scanning (n ¼ 17 [29. 8%]), with the remainder using pencil beam scanning (n ¼ 6 [10.6%] ). Prior studies have demonstrated that doses to the lung and OAR are lowest with actively scanned plans, especially in the area surrounding the PTV. 7 This is particularly relevant in targets abutting critical structures such as the central airway region, heart, and esophagus. The toxicity rates we have reported in this series may have been lower had the patients been treated exclusively by using IMPT techniques.
Regarding the ability to receive systemic therapy, we observed increased toxicity in patients receiving concurrent chemotherapy. However, increased toxicity did not translate into a detrimental effect on survival; the absolute figures for 1-year overall survival were higher with than without concurrent treatment (66% versus 43%, p ¼ 0.3) (Table 2, Fig. 3D ). This is consistent with prior series, which observed a significant improvement in overall survival with concurrent chemotherapy (hazard ratio ¼ 0.52, 95% confidence interval: 0.29-0.96, p ¼ 0.035). 21 Although selection bias may play a role in these outcomes, our and prior results suggest that concurrent chemotherapy is likely safe and tolerable and can be used in the reirradiation setting.
In the realm of systemic therapy, novel agents are continually in development and the expanded use of immunotherapy has shown potential for improved longterm outcomes. Indeed, the anti-programmed cell death 1 agents nivolumab and pembrolizumab were recently reported to improve survival in the second-line setting for NSCLC, [35] [36] [37] and pembrolizumab was found to improve survival over that with platinum-containing chemotherapy in the first-line setting for metastatic disease. 38 There are also ongoing studies, including at the authors' institution, that are investigating the use of immunotherapy in oligometastatic NSCLC after prior curative intent treatment (ClinicalTrials.gov identifier NCT02316002). Our current study did not investigate combination approaches with immunotherapy, but these novel approaches may yet represent an additional means of further progress in treating LR.
When SBRT was used, esophageal dose was found to be predictive of acute esophagitis, 39 and heart dose has been shown to significantly affect survival in the treatment of locally advanced lung cancer with chemoradiation. 40 Our analysis assessed the impact of elevated mean esophageal and heart doses on toxicities and outcomes. In keeping with earlier literature, we observed significantly higher rates of treatment-related toxicities with high mean esophageal and heart dose, which also translated to worse survival outcomes with increased esophageal dose ( Table 2 , Fig. 3F ). 39, 41, 42 Proper patient selection is clearly critical, as evidenced by the fact that even with the ability to complete a prescribed radiation course, significant toxicities may ensue. Indeed, the toxicities we have observed with the use of proton beam reirradiation further emphasize the need for careful and considered use of this modality, as the potential dosimetric advantages of a proton beam cannot by themselves eliminate toxicity and improve overall outcomes. As we investigate reirradiation further, we must continue to refine the techniques used and the ability of clinicians to optimally identify those most likely to benefit from retreatment. Although the study presented here focuses on proton reirradiation, the dosimetric and volumetric parameters predictive of increased toxicity may also be very well applicable to photon reirradiation. Ultimately, balancing the considerable risk of toxicity with the potential benefit is the crux of patient selection. On the basis of our results, the candidates most likely to tolerate a reirradiation course with the best outcomes are those who have good baseline performance status, have low-volume peripherally located tumors, are able to tolerate concurrent chemotherapy, and are treated with plans minimizing esophageal and heart dose, preferably with the use of a highly conformal treatment technique.
Conclusions
We have shown the feasibility of delivering reirradiation with PRT for NSCLC in carefully selected patients at the time of retreatment. However, we observed significant rates of treatment-related toxicities, and overall prognosis after disease progression remains guarded. We anticipate that continued advances in the area of molecular genomics and immunotherapy will help shape the future of NSCLC reirradiation. Additionally, longer follow-up, new and alternative therapies, increasing use of IMPT, and a growing body of detailed dosimetric analysis will expand the knowledge base and facilitate improved selection criteria and future improvements in tolerability and outcomes for patients receiving thoracic reirradiation.
